CAR-NK cells targeting MSLN, FRα, and MUC16

· Beijing Biotech

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CAR-NK cells targeting MSLN, FRα, and MUC16, covering 2026-03-18 to 2026-03-18. Get the full timeline:

Most recent: Clinical Trial Update: Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) [Phase 1, Phase 2]